Payment overview · 2025
General Payments
$1,234.06
35 reported records · 22 companies
Healthcare provider profile · identity verified
Khalid A Noori, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH BABYLON, NY · NPI 1023106838
Verified facts
What the public records show
CMS Open Payments records show Khalid A Noori, M.D. received $1,234.06 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Aranesp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lokelma by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuedexta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.75 | 15.7% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $148.39 | 12.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $139.33 | 11.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.99 | 10.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $112.81 | 9.1% | 1 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $71.50 | 5.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.43 | 4.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.20 | 4.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.70 | 4.0% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $34.44 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.41 | 2.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $26.17 | 2.1% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$25.01 | 2.0% | 1 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $24.57 | 2.0% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.06 | 1.9% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $20.48 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.17 | 1.6% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $19.05 | 1.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.04 | 1.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.79 | 1.5% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $17.52 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.25 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,234.06 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $193.75 | 5 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $148.39 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $139.33 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $112.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $98.90 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $71.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.99 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| Denali Vena Cava Filter Normalized: denali vena cava filter |
Device | Bard Peripheral Vascular, Inc. | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| Ventralight ST Normalized: ventralight st |
Device | Davol Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| ROSEN Normalized: rosen |
Device | Cook Medical LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1737 | 381 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1395 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 1360 | 248 |
| Eliquis | Apixaban | 1326 | 195 |
| Gabapentin | Gabapentin | 1067 | 201 |
| Furosemide | Furosemide | 1056 | 230 |
| Metoprolol Tartrate | Metoprolol Tartrate | 956 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 897 | 182 |
| Tamsulosin Hcl | Tamsulosin Hcl | 893 | 187 |
| Mirtazapine | Mirtazapine | 892 | 158 |
| Sertraline Hcl | Sertraline Hcl | 859 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 791 | 193 |
| Escitalopram Oxalate | Escitalopram Oxalate | 725 | 121 |
| Potassium Chloride | Potassium Chloride | 668 | 109 |
| Trazodone Hcl | Trazodone Hcl | 634 | 114 |
| Metformin Hcl | Metformin Hcl | 627 | 135 |
| Levetiracetam | Levetiracetam | 623 | 97 |
| Donepezil Hcl | Donepezil Hcl | 587 | 81 |
| Losartan Potassium | Losartan Potassium | 530 | 121 |
| Lisinopril | Lisinopril | 489 | 95 |
| Quetiapine Fumarate | Quetiapine Fumarate | 470 | 89 |
| Montelukast Sodium | Montelukast Sodium | 453 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 391 | 106 |
| Divalproex Sodium | Divalproex Sodium | 387 | 64 |
| Clozapine | Clozapine | 378 | 15 |
| Famotidine | Famotidine | 377 | 102 |
| Memantine Hcl | Memantine Hcl | 363 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 357 | 68 |
| Carvedilol | Carvedilol | 348 | 78 |
| Baclofen | Baclofen | 322 | 43 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 304 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 303 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 83 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 298 | 66 |
| Torsemide | Torsemide | 293 | 47 |
| Finasteride | Finasteride | 290 | 58 |
| Santyl | Collagenase Clostridium Hist. | 275 | 66 |
| Olanzapine | Olanzapine | 257 | 43 |
| Sodium Chloride | 0.9 % Sodium Chloride | 242 | 111 |
| Simvastatin | Simvastatin | 231 | 59 |
| Risperidone | Risperidone | 226 | 40 |
| Xarelto | Rivaroxaban | 217 | 31 |
| Omeprazole | Omeprazole | 213 | 58 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 206 | 89 |
| Prednisone | Prednisone | 206 | 63 |
| Allopurinol | Allopurinol | 205 | 39 |
| Scopolamine | Scopolamine | 174 | 22 |
| Enoxaparin Sodium | Enoxaparin Sodium | 168 | 35 |
| Januvia | Sitagliptin Phosphate | 166 | 21 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 161 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 160 | 29 |
| Enalapril Maleate | Enalapril Maleate | 156 | 22 |
| Spironolactone | Spironolactone | 152 | 41 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 151 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 147 | 18 |
| Lactulose | Lactulose | 147 | 38 |
| Benztropine Mesylate | Benztropine Mesylate | 142 | 20 |
| Farxiga | Dapagliflozin Propanediol | 140 | 23 |
| Latanoprost | Latanoprost | 140 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 32 |
| Lamotrigine | Lamotrigine | 137 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 136 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 135 | 16 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 129 | 45 |
| Buspirone Hcl | Buspirone Hcl | 127 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 48 |
| Midodrine Hcl | Midodrine Hcl | 118 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 26 |
| Nifedipine Er | Nifedipine | 115 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 51 |
| Alprazolam | Alprazolam | 114 | 39 |
| Clonazepam | Clonazepam | 113 | 28 |
| Ezetimibe | Ezetimibe | 112 | 33 |
| Atenolol | Atenolol | 107 | 14 |
| Jardiance | Empagliflozin | 106 | 27 |
| Aripiprazole | Aripiprazole | 104 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 13 |
| Daptomycin | Daptomycin | 101 | suppressed |
| Digoxin | Digoxin | 101 | 22 |
| Propranolol Hcl | Propranolol Hcl | 100 | 17 |
| Lorazepam | Lorazepam | 97 | 34 |
| Silver Sulfadiazine | Silver Sulfadiazine | 96 | 47 |
| Humalog Kwikpen U-100 | Insulin Lispro | 93 | 12 |
| Budesonide | Budesonide | 90 | 18 |
| Entresto | Sacubitril/Valsartan | 90 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 90 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 23 |
| Haloperidol | Haloperidol | 87 | 14 |
| Labetalol Hcl | Labetalol Hcl | 87 | 19 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 86 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 20 |
| Brimonidine Tartrate | Brimonidine Tartrate | 85 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 84 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 39 |
| Valsartan | Valsartan | 83 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 29 |
| Warfarin Sodium | Warfarin Sodium | 79 | 20 |
| Methenamine Hippurate | Methenamine Hippurate | 78 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 27 |
| Nystatin | Nystatin | 77 | 40 |
| Azithromycin | Azithromycin | 75 | 47 |
| Meloxicam | Meloxicam | 74 | 25 |
| Memantine Hcl Er | Memantine Hcl | 72 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 26 |
| Bumetanide | Bumetanide | 70 | suppressed |
| Fetroja | Cefiderocol Sulfate Tosylate | 70 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 68 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 68 | suppressed |
| Amantadine | Amantadine Hcl | 67 | suppressed |
| Bupropion Xl | Bupropion Hcl | 67 | 18 |
| Novolog Flexpen | Insulin Aspart | 66 | 27 |
| Sevelamer Carbonate | Sevelamer Carbonate | 66 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 65 | suppressed |
| Anastrozole | Anastrozole | 64 | suppressed |
| Glipizide | Glipizide | 63 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 63 | 43 |
| Carbamazepine | Carbamazepine | 62 | suppressed |
| Gemtesa | Vibegron | 62 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 44 |
| Divalproex Sodium Er | Divalproex Sodium | 58 | 11 |
| Ibuprofen | Ibuprofen | 58 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 22 |
| Insulin Aspart Flexpen | Insulin Aspart | 57 | 13 |
| Methocarbamol | Methocarbamol | 57 | 25 |
| Brilinta | Ticagrelor | 56 | suppressed |
| Sucralfate | Sucralfate | 55 | 15 |
| Linzess | Linaclotide | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 19 |
| Vancomycin Hcl | Vancomycin Hcl | 52 | 17 |
| Alendronate Sodium | Alendronate Sodium | 51 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 50 | 28 |
| Metformin Hcl Er | Metformin Hcl | 48 | 13 |
| Mounjaro | Tirzepatide | 48 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 28 |
| Procrit | Epoetin Alfa | 48 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 47 | 16 |
| Ozempic | Semaglutide | 46 | 19 |
| Xifaxan | Rifaximin | 46 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | 21 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 34 |
| Silodosin | Silodosin | 44 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 20 |
| Fluconazole | Fluconazole | 43 | 14 |
| Ssd | Silver Sulfadiazine | 43 | 27 |
| Ertapenem | Ertapenem Sodium | 42 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 32 |
| Tradjenta | Linagliptin | 42 | 11 |
| Trulicity | Dulaglutide | 42 | 16 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 18 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 18 |
| Insulin Lispro | Insulin Lispro | 41 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 13 |
| Admelog Solostar | Insulin Lispro | 40 | 14 |
| Ramipril | Ramipril | 40 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 40 | suppressed |
| Timolol Maleate | Timolol Maleate | 39 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 23 |
| Ranolazine Er | Ranolazine | 38 | suppressed |
| Ursodiol | Ursodiol | 38 | suppressed |
| Valproic Acid | Valproic Acid | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 37 | 22 |
| Topiramate | Topiramate | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Calcium Acetate | Calcium Acetate | 36 | suppressed |
| Cyclosporine | Cyclosporine | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 31 |
| Naproxen | Naproxen | 36 | 22 |
| Ceftriaxone | Ceftriaxone Sodium | 35 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 26 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 35 | suppressed |
| Risperidone Er | Risperidone Microspheres | 35 | suppressed |
| Cilostazol | Cilostazol | 34 | suppressed |
| Nystop | Nystatin | 34 | 21 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 34 | 24 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 33 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 32 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 32 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Generlac | Lactulose | 32 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 32 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 16 |
| Primidone | Primidone | 32 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 32 | 13 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 31 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 30 | suppressed |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 29 | 21 |
| Levofloxacin | Levofloxacin | 28 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Metolazone | Metolazone | 27 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 11 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 26 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | 11 |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Alogliptin | Alogliptin Benzoate | 24 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 11 |
| Risperdal Consta | Risperidone Microspheres | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Metronidazole | Metronidazole | 23 | 14 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 22 | suppressed |
| Nadolol | Nadolol | 22 | suppressed |
| Zerbaxa | Ceftolozane/Tazobactam | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 21 | 16 |
| Vancomycin Hcl-0.9% Nacl | Vancomycin/0.9 % Sod Chloride | 21 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | 11 |
| Tadalafil | Tadalafil | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 17 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Meropenem | Meropenem | 16 | suppressed |
| Mesalamine Er | Mesalamine | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | 11 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Mesalamine Dr | Mesalamine | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Nitro-Dur | Nitroglycerin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Verquvo | Vericiguat | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Budesonide Dr | Budesonide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 14 | 12 |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Acarbose | Acarbose | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Tacrolimus | Tacrolimus | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 13 | suppressed |
| Avycaz | Ceftazidime/Avibactam | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Zoledronic Acid | Zoledronic Acid/Mannitol-Water | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,234.06 · 35 records | Novo Nordisk Inc | BREZTRI, CAPLYTA, Denali Vena Cava Filter, FARAPULSE, FREESTYLE LIBRE 3, Flexitouch Plus, IBSRELA, Indigo System, Kerendia, LEQVIO, MYFEMBREE, Nimbl, Ozempic, PURIFIED CORTROPHIN GEL, RENASYS TOUCH, REPATHA, REXULTI, ROSEN, Rybelsus, SUBLOCADE, VALTOCO, Ventralight ST | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error